FDA grants Priority Review to Johnson & Johnson’s RYBREVANT FASPRO™ sBLA for subcutaneous treatment in advanced head and neck cancer
The U.S. Food and Drug Administration has accepted a supplemental biologics license application for RYBREVANT FASPRO, potentially positioning amivantamab-based therapy as a first-in-class, EGFR- and MET-targeted option delivered under the skin.